{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:21Z","timestamp":1793272281974,"version":"4.5.0"},"reference-count":86,"publisher":"The Journal of Rheumatology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To systematically review all existing Sj\u00f6gren disease (SjD)-related instruments reported in clinical trials for SjD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We systematically searched Medline (PubMed) and EMBASE between January 2002 and March 2023 to identify all randomized controlled trials (RCTs) using both a manual approach and artificial intelligence software (Bibliography BOT). We extracted all the instruments used as primary or secondary outcomes and assessed whether the study succeeded in improving the outcome. We also classified the instruments according to the recently defined preliminary outcome domains.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 5420 references, 60 RCTs were included, focusing either on overall disease manifestations (53%) or on a single organ\/symptom (eg, dry eyes [17%], xerostomia [15%], fatigue [12%], or pulmonary function [3%]). Primary outcomes included measures of oral or ocular dryness, patient-reported outcomes (PROs), systemic activity, and other outcomes. Common instruments used were European Alliance of Associations for Rheumatology (EULAR) Sj\u00f6gren Syndrome Disease Activity Index (ESSDAI), EULAR Sj\u00f6gren Syndrome Patient-Reported Index, Schirmer-I test for unstimulated salivary flow, and IgG levels. ESSDAI was a primary outcome in 11 studies, with 45% of studies reaching significance, whereas none of the 16 studies with ESSDAI as a secondary outcome reached significance. PROs were the primary outcome in 34 studies. Glandular function measurements varied, with unstimulated salivary flow as the most commonly measured outcome. Life impact was assessed more frequently as a secondary outcome. Only 2 studies focused on biological activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our review highlighted the heterogeneity of SjD RCTs in both the study designs and outcomes. The use of PROs and composite outcomes has increased in recent years, highlighting a shift from objective dryness measures to more holistic patient-centered outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1012","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:35:16Z","timestamp":1743496516000},"page":"858-872","source":"Crossref","is-referenced-by-count":9,"title":["A Systematic Review of Clinical Trial Designs and Outcome Measures in Sj\u00f6gren Disease Randomized Controlled Trials"],"prefix":"10.3899","volume":"52","author":[{"given":"Maxime","family":"Beydon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-3824","authenticated-orcid":false,"given":"Yann","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Foulquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8021-2539","authenticated-orcid":false,"given":"Coralie","family":"Bouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Hammitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5293-4185","authenticated-orcid":false,"given":"Sara S.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1856","authenticated-orcid":false,"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2025090105350878000_52.9.858.1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/art.41676","article-title":"Sj\u00f6gren\u2019s disease, not syndrome","volume":"73","author":"Baer","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350878000_52.9.858.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu365"},{"key":"2025090105350878000_52.9.858.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21887"},{"key":"2025090105350878000_52.9.858.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj004"},{"key":"2025090105350878000_52.9.858.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200402"},{"key":"2025090105350878000_52.9.858.6","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619"},{"key":"2025090105350878000_52.9.858.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743"},{"key":"2025090105350878000_52.9.858.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200460"},{"key":"2025090105350878000_52.9.858.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21991"},{"key":"2025090105350878000_52.9.858.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.010"},{"key":"2025090105350878000_52.9.858.12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/BOR.0b013e3283524c37","article-title":"How to assess treatment efficacy in Sj\u00f6gren\u2019s syndrome?","volume":"24","author":"Vissink","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2025090105350878000_52.9.858.13","doi-asserted-by":"crossref","first-page":"152385","DOI":"10.1016\/j.semarthrit.2024.152385","article-title":"Identification of outcome domains in primary Sj\u00f6gren\u2019s disease: a scoping review by the OMERACT Sj\u00f6gren disease working group","volume":"65","author":"Nguyen","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025090105350878000_52.9.858.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.2.116"},{"key":"2025090105350878000_52.9.858.15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis, revised version"},{"key":"2025090105350878000_52.9.858.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21591"},{"key":"2025090105350878000_52.9.858.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.39859"},{"key":"2025090105350878000_52.9.858.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212268"},{"key":"2025090105350878000_52.9.858.19","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/art.39088","article-title":"Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"67","author":"Jousse-Joulin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350878000_52.9.858.20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/rheumatology\/kez370","article-title":"Can artificial intelligence replace manual search for systematic literature? Review on cutaneous manifestations in primary Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Orgeolet","year":"2020","journal-title":"Rheumatology"},{"key":"2025090105350878000_52.9.858.21","first-page":"2553","article-title":"Pathogenesis-based treatments in primary Sjogren\u2019s syndrome using artificial intelligence and advanced machine learning techniques: a systematic literature review","volume":"14","author":"Foulquier","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2025090105350878000_52.9.858.22","doi-asserted-by":"crossref","first-page":"105109","DOI":"10.1016\/j.jbspin.2020.105109","article-title":"Can we use artificial intelligence for systematic literature review in rheumatology?","volume":"88","author":"Foulquier","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090105350878000_52.9.858.23","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"Van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.24","doi-asserted-by":"crossref","first-page":"e163030","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"2025090105350878000_52.9.858.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2025090105350878000_52.9.858.26","doi-asserted-by":"crossref","first-page":"e2241451","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose interleukin 2 for primary Sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025090105350878000_52.9.858.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222054"},{"key":"2025090105350878000_52.9.858.28","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","article-title":"The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients","volume":"40","author":"Jiang","year":"2020","journal-title":"Int Ophthalmol"},{"key":"2025090105350878000_52.9.858.30","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2025090105350878000_52.9.858.32","doi-asserted-by":"crossref","first-page":"1315432","DOI":"10.1155\/2017\/1315432","article-title":"Effectiveness of traditional Chinese medicine compound JieDuTongLuoSheng Jin granules treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"2017","author":"Li","year":"2017","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025090105350878000_52.9.858.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.27314"},{"key":"2025090105350878000_52.9.858.34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10067-018-4315-8","article-title":"The efficacy and safety of total glucosides of peony in the treatment of primary Sj\u00f6gren\u2019s syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial","volume":"38","author":"Liu","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090105350878000_52.9.858.35","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.36","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"2025090105350878000_52.9.858.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.510"},{"key":"2025090105350878000_52.9.858.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.11199"},{"key":"2025090105350878000_52.9.858.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.20146"},{"key":"2025090105350878000_52.9.858.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.20299"},{"key":"2025090105350878000_52.9.858.41","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031393"},{"key":"2025090105350878000_52.9.858.42","doi-asserted-by":"publisher","DOI":"10.1186\/1477-5751-6-11"},{"key":"2025090105350878000_52.9.858.43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025090105350878000_52.9.858.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7682"},{"key":"2025090105350878000_52.9.858.45","first-page":"2721","article-title":"Traditional Chinese medicine compound Sheng JinRunZaoYangXue granules for treatment of primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"127","author":"Hu","year":"2014","journal-title":"Chin Med J"},{"key":"2025090105350878000_52.9.858.46","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren\u2019s syndrome: a double-blind randomized control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"2025090105350878000_52.9.858.47","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350878000_52.9.858.48","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.16442","article-title":"Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in Sj\u00f6gren syndrome: a double-blind randomized controlled trial","volume":"179","author":"Cifuentes","year":"2018","journal-title":"Br J Dermatol"},{"key":"2025090105350878000_52.9.858.49","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of Baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a Phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350878000_52.9.858.50","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0140-6736(22)01538-0","article-title":"Ianalumab in Sj\u00f6gren\u2019s syndrome: what can we learn from lupus trials? \u2013 Authors\u2019 reply","volume":"400","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2025090105350878000_52.9.858.51","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025090105350878000_52.9.858.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599"},{"key":"2025090105350878000_52.9.858.53","doi-asserted-by":"crossref","first-page":"744194","DOI":"10.3389\/fmed.2021.744194","article-title":"Traditional Chinese medicine in patients with primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"2025090105350878000_52.9.858.54","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology"},{"key":"2025090105350878000_52.9.858.55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","article-title":"Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: a randomized, placebo-controlled clinical trial","volume":"50","author":"Shao","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025090105350878000_52.9.858.56","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"2025090105350878000_52.9.858.57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.explore.2021.08.002","article-title":"Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sj\u00f6gren\u2019s syndrome: a randomized controlled trial","volume":"18","author":"Shao","year":"2022","journal-title":"Explore"},{"key":"2025090105350878000_52.9.858.58","doi-asserted-by":"crossref","first-page":"878218","DOI":"10.3389\/fmed.2022.878218","article-title":"Efficacy and safety of acupuncture on symptomatic improvement in primary Sj\u00f6gren\u2019s syndrome: a randomized controlled trial","volume":"9","author":"Zhou","year":"2022","journal-title":"Front Med"},{"key":"2025090105350878000_52.9.858.59","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.003889"},{"key":"2025090105350878000_52.9.858.60","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701537"},{"key":"2025090105350878000_52.9.858.61","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5301\/ejo.5000229","article-title":"Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sj\u00f6gren syndrome","volume":"23","author":"Aragona","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"2025090105350878000_52.9.858.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2015.04.004"},{"key":"2025090105350878000_52.9.858.63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/jop.2016.0149","article-title":"Tear film stability in Sj\u00f6gren syndrome patients treated with hyaluronic acid versus crosslinked hyaluronic acid-based eye drops","volume":"33","author":"Cagini","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025090105350878000_52.9.858.64","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/09273948.2019.1587470","article-title":"Evaluation of the efficacy and safety of a novel 0.05% cyclosporin A topical nanoemulsion in primary Sj\u00f6gren\u2019s syndrome dry eye","volume":"28","author":"Kang","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"2025090105350878000_52.9.858.65","first-page":"269","article-title":"Oral pilocarpine for the treatment of dry eye in patients with Sj\u00f6gren\u2019s syndrome","volume":"85","author":"Felberg","year":"2022","journal-title":"Arq Bras Oftalmol"},{"key":"2025090105350878000_52.9.858.66","doi-asserted-by":"publisher","DOI":"10.1177\/1120672121992680"},{"key":"2025090105350878000_52.9.858.67","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2769-1"},{"key":"2025090105350878000_52.9.858.68","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1097\/OPX.0000000000000668","article-title":"Effect of lid debridement-scaling in Sj\u00f6gren syndrome dry eye","volume":"92","author":"Ngo","year":"2015","journal-title":"Optom Vis Sci"},{"key":"2025090105350878000_52.9.858.69","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-007-0159-3"},{"key":"2025090105350878000_52.9.858.70","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1754-4505.2010.00158.x","article-title":"Effect of omega-3 and vitamin E supplementation on dry mouth in patients with Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Singh","year":"2010","journal-title":"Spec Care Dentist"},{"key":"2025090105350878000_52.9.858.71","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0714.2011.01038.x","article-title":"Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sj\u00f6gren\u2019s syndrome: a randomized controlled trial","volume":"40","author":"da Silva Marques","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"2025090105350878000_52.9.858.72","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00784-015-1444-1","article-title":"Efficacy of pastes containing CPP-ACP and CPP-ACFP in patients with Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Peric","year":"2015","journal-title":"Clin Oral Investig"},{"key":"2025090105350878000_52.9.858.73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/odi.13251","article-title":"Patient-related outcomes in Sj\u00f6gren syndrome treated with stimulants of salivary secretion: randomized clinical trial","volume":"26","author":"da Mata","year":"2020","journal-title":"Oral Dis"},{"key":"2025090105350878000_52.9.858.74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10067-017-3898-9","article-title":"Low-level laser therapy for xerostomia in primary Sj\u00f6gren\u2019s syndrome: a randomized trial","volume":"37","author":"Fidelix","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2025090105350878000_52.9.858.75","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212672"},{"key":"2025090105350878000_52.9.858.76","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/odi.13019","article-title":"Effects of Xerostom\u00ae products on xerostomia in primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"25","author":"L\u00f3pez-Pintor","year":"2019","journal-title":"Oral Dis"},{"key":"2025090105350878000_52.9.858.77","doi-asserted-by":"crossref","first-page":"1039599","DOI":"10.3389\/fimmu.2022.1039599","article-title":"A randomized controlled trial to verify the irrigation of salivary glands in relieving xerostomia in patients with Sj\u00f6gren\u2019s syndrome","volume":"13","author":"Du","year":"2022","journal-title":"Front Immunol"},{"key":"2025090105350878000_52.9.858.78","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083865"},{"key":"2025090105350878000_52.9.858.79","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071563"},{"key":"2025090105350878000_52.9.858.80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/acr.20022","article-title":"Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Virkki","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025090105350878000_52.9.858.81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123"},{"key":"2025090105350878000_52.9.858.82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00296-018-4213-z","article-title":"Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sj\u00f6gren\u2019s syndrome: a randomized-controlled trial","volume":"39","author":"Miyamoto","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090105350878000_52.9.858.83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.41489","article-title":"Improvement of severe fatigue following nuclease therapy in patients with primary Sj\u00f6gren\u2019s syndrome: a randomized clinical trial","volume":"73","author":"Posada","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090105350878000_52.9.858.84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.brs.2020.12.004","article-title":"Transcranial direct current stimulation for fatigue in patients with Sjogren\u2019s syndrome: a randomized, double-blind pilot study","volume":"14","author":"Pinto","year":"2021","journal-title":"Brain Stimul"},{"key":"2025090105350878000_52.9.858.85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/03009742.2019.1602880","article-title":"Effectiveness of resistance exercise in functional fitness in women with primary Sj\u00f6gren\u2019s syndrome: randomized clinical trial","volume":"49","author":"Minali","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2025090105350878000_52.9.858.86","doi-asserted-by":"crossref","first-page":"719592","DOI":"10.3389\/fmed.2021.719592","article-title":"Cardiovascular effect of physical exercise on primary Sjogren\u2019s syndrome (pSS): randomized trial","volume":"8","author":"Garcia","year":"2021","journal-title":"Front Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:35:33Z","timestamp":1756730133000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":86,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.3899\/jrheum.2024-1012"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1012","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}